Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Senseonics (NYSE American: SENS) reported third quarter 2025 results with $8.1M revenue, up 90% YoY, driven by a 160% increase in U.S. new patient starts. Q3 gross profit was $3.5M versus a gross loss in Q3 2024. Net loss narrowed to $19.5M ($0.43/share) from $24.0M a year earlier. Management completed a 1-for-20 reverse stock split (approx. 41M shares outstanding) and plans to move listing to Nasdaq Global Market on Nov 17, 2025. Full-year 2025 revenue outlook is ~$35M, with expected 2025 gross margins of 35–40% and ~$60M cash used in operations.
Senseonics (NYSE American: SENS) will release third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a conference call and concurrent webcast to review Q3 2025 performance starting at 4:30 p.m. Eastern Time the same day.
The webcast link will be posted and archived under Investor Relations > Events & Publications at www.senseonics.com. To join the call, dial 1-800-343-5172 (US/Canada) or 1-203-518-9856 (International) and use passcode SENSQ3, connecting about ten to five minutes before the start time.
Senseonics (NYSE American: SENS) reported preliminary unaudited Q3 2025 revenue of $8.1 million, a 91% increase versus Q3 2024, driven by ~160% new patient growth in the U.S. and record monthly new patient starts in September 2025. The company cited increased direct-to-consumer marketing and bringing sales and marketing in-house as drivers of momentum for its Eversense 365 CGM.
Senseonics also announced a 1-for-20 reverse stock split, reducing issued shares from ~816 million to ~41 million, expected effective at 5:00 p.m. ET on October 17, 2025, with post-split trading beginning October 20, 2025 under symbol SENS.
Senseonics (NYSE:SENS) has signed a memorandum of understanding with Ascensia Diabetes Care to take over commercial operations for Eversense® CGM systems starting January 1, 2026. The agreement aims to unite Eversense's R&D, manufacturing, and commercial activities under Senseonics' control.
The transfer comes after Ascensia's successful launch of Eversense 365, the world's first one-year CGM system, in October 2024. Most of Ascensia's Eversense commercial team, including CGM President Brian Hansen, will transition to Senseonics. The companies expect minimal disruption for business partners, patients, and providers during the transition.
Senseonics (NYSE American: SENS) announced a significant strategic shift in its Eversense 365 commercialization strategy. The company has signed a Memorandum of Understanding to take over all global commercialization and distribution from Ascensia Diabetes Care, effective January 1, 2026.
Key developments include the appointment of Brian Hansen as Chief Commercial Officer and an expanded debt facility up to $100 million with Hercules Capital to fund the commercial organization. The company expects 2025 global net revenue of $34-38 million and projects gross margin expansion to 50% in 2026, increasing to over 70% at scale.
For 2025, Senseonics anticipates doubling its global patient base, with gross margins between 32.5% and 37.5%. Cash used in operations is expected to be approximately $60 million.
Senseonics Holdings (NYSE American: SENS) reported Q2 2025 financial results, achieving $6.6 million in revenue, up 37% year-over-year, driven by a 79% increase in U.S. new patient starts. The company raised $77.8 million in total gross proceeds, including $57.5 million from a public offering and $20.3 million from Abbott.
Q2 net loss improved to $14.5 million ($0.02 per share) from $20.3 million in Q2 2024. The company expanded its DTC advertising campaign, completed provider transition to Eon Care, and entered a commercial agreement to integrate Sequel Med Tech's twiist™ AID system with Eversense 365.
For full-year 2025, Senseonics maintains guidance of $34-38 million in global net revenue, expecting to double its global patient base with gross margins between 32.5% and 37.5%.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term implantable continuous glucose monitoring systems for diabetes patients, has scheduled its second quarter 2025 earnings release and conference call for August 6, 2025.
The financial results will be released after market close, followed by a management conference call at 4:30 PM Eastern Time. Investors can access the call via phone (US/Canada: 1-800-225-9448, International: 1-203-518-9708, passcode: SENSQ2) or through a webcast available on the company's investor relations website.
Senseonics Holdings (NYSE: SENS) has successfully completed two capital raising initiatives: a public offering and a private placement. The public offering raised $57.5 million through the sale of 115 million shares at $0.50 per share, including the full exercise of underwriters' option for 15 million additional shares. Additionally, Abbott Laboratories participated in a private placement, acquiring 40.5 million shares (4.99% ownership) for $20.3 million.
The combined proceeds will fund the ongoing launch of Eversense 365, their implantable continuous glucose monitoring system for diabetes patients, pipeline product development, working capital, and general corporate purposes. The offering was managed by TD Cowen, Barclays, RBC Capital Markets, and Lake Street.
Senseonics Holdings (NYSE: SENS) has announced the pricing of a $50 million public offering of common stock, consisting of 100,000,000 shares priced at $0.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 15,000,000 shares. In a concurrent private placement, Abbott Laboratories will purchase shares at $0.50 per share, representing 4.99% of Senseonics' post-offering outstanding common stock.
The offering is expected to close on May 19, 2025, with TD Cowen and Barclays acting as joint book-running managers. The net proceeds will be used to fund the ongoing launch of Eversense 365 and pipeline product development, along with working capital and general corporate purposes.